Conservation of DNA-binding specificity and oligomerisation properties within the p53 family

BMC Genomics

Volumn 10, Issue , 2009, Pages

  Brandt, Tobias ^a   Petrovich, Miriana ^a   Joerger, Andreas C ^a   Veprintsev, Dmitry B ^b  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CPG ISLAND; DNA BINDING; DNA METHYLATION; FLUORESCENCE SPECTROSCOPY; GENETIC CONSERVATION; GENOME; HUMAN; MOLECULAR CLONING; MOLECULAR DYNAMICS; OLIGOMERIZATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; DNA SEQUENCE; ENZYME SPECIFICITY; GENETICS; HUMAN GENOME; METABOLISM; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PROTEIN MULTIMERIZATION; TUMOR SUPPRESSOR GENE;

BINDING SITES; CONSERVED SEQUENCE; DNA METHYLATION; DNA-BINDING PROTEINS; GENES, P53; GENOME, HUMAN; HUMANS; MULTIGENE FAMILY; NUCLEAR PROTEINS; PROTEIN MULTIMERIZATION; SEQUENCE ANALYSIS, DNA; SUBSTRATE SPECIFICITY; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 74549130412     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-10-628     Document Type: Article

References (57)

1. Wilson D, Charoensawan V, Kummerfeld SK, Teichmann SA. DBD--taxonomically broad transcription factor predictions: new content and functionality. Nucleic Acids Res 2008, (36 Database):D88-92. 2238844, 18073188.
2. Amoutzias GD, Veron AS, Weiner J, Robinson-Rechavi M, Brnberg-Bauer E, Oliver SG, Robertson DL. One billion years of bZIP transcription factor evolution: conservation and change in dimerization and DNA-binding site specificity. Molecular biology and evolution 2007, 24(3):827-835. 10.1093/molbev/msl211, 17194801.
3. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000, 20(2):429-440. 10.1128/MCB.20.2.429-440.2000, 85097, 10611221.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408(6810):307-310. 10.1038/35042675, 11099028.
5. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2(8):594-604. 10.1038/nrc864, 12154352.
6. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007, 26(15):2226-2242. 10.1038/sj.onc.1210291, 17401432.
7. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28(6):622-629. 10.1002/humu.20495, 17311302.
8. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004, 2(7):371-386.
9. Jegga AG, Inga A, Menendez D, Aronow BJ, Resnick MA. Functional evolution of the p53 regulatory network through its target response elements. Proc Natl Acad Sci USA 2008, 105(3):944-949. 10.1073/pnas.0704694105, 2242714, 18187580.
10. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annual review of biochemistry 2008, 77:557-582. 10.1146/annurev.biochem.77.060806.091238, 18410249.
11. Scoumanne A, Harms KL, Chen X. Structural basis for gene activation by p53 family members. Cancer Biol Ther 2005, 4(11):1178-1185.
12. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1(1):45-49. 10.1038/ng0492-45, 1301998.
13. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992, 12(6):2866-2871. 364481, 1588974.
14. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA, Resnick MA. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci USA 2005, 102(18):6431-6436. 10.1073/pnas.0501721102, 1088378, 15843459.
15. Veprintsev DB, Fersht AR. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 2008, 36(5):1589-1598. 10.1093/nar/gkm1040, 2275157, 18234719.
16. Schavolt KL, Pietenpol JA. p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell arrest DNA repair and apoptosis. Oncogene 2007, 26(42):6125-6132. 10.1038/sj.onc.1210441, 17404570.
17. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, Kim MS, Wu G, Nomoto S, Trink B, Sidransky D. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 2005, 25(14):6077-6089. 10.1128/MCB.25.14.6077-6089.2005, 1168821, 15988020.
18. Lokshin M, Li Y, Gaiddon C, Prives C. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res 2007, 35(1):340-352. 10.1093/nar/gkl1047, 1802567, 17170001.
19. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006, 13(6):962-972. 10.1038/sj.cdd.4401914, 16601753.
20. Petrovich M, Veprintsev DB. Effects of CpG methylation on recognition of DNA by the tumour suppressor p53. J Mol Biol 2009, 386(1):72-80. 10.1016/j.jmb.2008.11.054, 2666794, 19084536.
21. Weinberg RL, Veprintsev DB, Fersht AR. Cooperative binding of tetrameric p53 to DNA. J Mol Biol 2004, 341(5):1145-1159. 10.1016/j.jmb.2004.06.071, 15321712.
22. Veprintsev DB, Freund SM, Andreeva A, Rutledge SE, Tidow H, Canadillas JM, Blair CM, Fersht AR. Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci USA 2006, 103(7):2115-2119. 10.1073/pnas.0511130103, 1413758, 16461914.
23. MacGregor IK, Anderson AL, Laue TM. Fluorescence detection for the XLI analytical ultracentrifuge. Biophys Chem 2004, 108(1-3):165-185. 10.1016/j.bpc.2003.10.018, 15043928.
24. Adams SR, Campbell RE, Gross LA, Martin BR, Walkup GK, Yao Y, Llopis J, Tsien RY. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc 2002, 124(21):6063-6076. 10.1021/ja017687n, 12022841.
25. Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci USA 2009, 106(42):17705-17710. 10.1073/pnas.0905867106, 19815500.
26. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res 1990, 18(20):6097-6100. 10.1093/nar/18.20.6097, 332411, 2172928.
27. Schneider TD, Stormo GD, Gold L, Ehrenfeucht A. Information content of binding sites on nucleotide sequences. J Mol Biol 1986, 188(3):415-431. 10.1016/0022-2836(86)90165-8, 3525846.
28. Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and chromatin. Cell 1999, 99(5):451-454. 10.1016/S0092-8674(00)81532-9, 10589672.
29. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33:245-254. 10.1038/ng1089, 12610534.
30. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 1988, 2(9):1136-1143. 10.1101/gad.2.9.1136, 3192075.
31. Ou HD, Lohr F, Vogel V, Mantele W, Dotsch V. Structural evolution of C-terminal domains in the p53 family. EMBO J 2007, 26(14):3463-3473. 10.1038/sj.emboj.7601764, 1933395, 17581633.
32. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267(5203):1498-1502. 10.1126/science.7878469, 7878469.
33. Clore GM, Ernst J, Clubb R, Omichinski JG, Kennedy WM, Sakaguchi K, Appella E, Gronenborn AM. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 1995, 2(4):321-333. 10.1038/nsb0495-321, 7796267.
34. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1994, 1(12):877-890. 10.1038/nsb1294-877, 7773777.
35. Coutandin D, Lohr F, Niesen FH, Ikeya T, Weber TA, Schafer B, Zielonka EM, Bullock AN, Yang A, Guntert P, Knapp S, McKeon F, Ou HD, Dotsch V. Conformational stability and activity of p73 require a second helix in the tetramerization domain. Cell Death Differ 2009, 16(12):1582-1589. 10.1038/cdd.2009.139, 19763140.
36. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002, 9(1):12-16. 10.1038/nsb730, 11753428.
37. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245(1-2):96-102. 10.1016/j.canlet.2005.12.039, 16494995.
38. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA 2005, 102(13):4735-4740. 10.1073/pnas.0501459102, 555715, 15781852.
39. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009, 284(20):13804-13811. 10.1074/jbc.M901351200, 19297317.
40. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006, 22(6):741-753. 10.1016/j.molcel.2006.05.015, 16793544.
41. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265(5170):346-355. 10.1126/science.8023157, 8023157.
42. Jin S, Martinek S, Joo WS, Wortman JR, Mirkovic N, Sali A, Yandell MD, Pavletich NP, Young MW, Levine AJ. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci USA 2000, 97(13):7301-7306. 10.1073/pnas.97.13.7301, 16540, 10860994.
43. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 2005, 280(16):16030-16037. 10.1074/jbc.M500179200, 15703170.
44. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG, Lohrum M. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 2008, 36(11):3639-3654. 10.1093/nar/gkn232, 2441782, 18474530.
45. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, Struhl K. Relationships between p63 Binding, DNA Sequence Transcription Activity and Biological Function in Human Cells. Mol Cell 2006, 24(4):593-602. 10.1016/j.molcel.2006.10.018, 17188034.
46. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell 2006, 124(1):207-219. 10.1016/j.cell.2005.10.043, 16413492.
47. Noureddine MA, Menendez D, Campbell MR, Bandele OJ, Horvath MM, Wang X, Pittman GS, Chorley BN, Resnick MA, Bell DA. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. PLoS genetics 2009, 5(5):e1000462. 10.1371/journal.pgen.1000462, 2667269, 19424414.
48. Okorokov AL, Orlova EV. Structural biology of the p53 tumour suppressor. Curr Opin Struct Biol 2009, 19(2):197-202. 10.1016/j.sbi.2009.02.003, 19286366.
49. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9(5):402-412. 10.1038/nrm2395, 18431400.
50. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 2008, 4(6):e1000104. 10.1371/journal.pgen.1000104, 2518093, 18714371.
51. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009, 9(10):724-737. 10.1038/nrc2730, 19776742.
52. Joerger AC, Allen MD, Fersht AR. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 2004, 279(2):1291-1296. 10.1074/jbc.M309732200, 14534297.
53. Nikolova PV, Henckel J, Lane DP, Fersht AR. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci USA 1998, 95(25):14675-14680. 10.1073/pnas.95.25.14675, 24508, 9843948.
54. Hipps DS, Packman LC, Allen MD, Fuller C, Sakaguchi K, Appella E, Perham RN. The peripheral subunit-binding domain of the dihydrolipoyl acetyltransferase component of the pyruvate dehydrogenase complex of Bacillus stearothermophilus: preparation and characterization of its binding to the dihydrolipoyl dehydrogenase component. Biochem J 1994, 297(Pt 1):137-143. 1137802, 8280091.
55. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J 2002, 82(2):1096-1111. 10.1016/S0006-3495(02)75469-6, 1301916, 11806949.
56. Rajagopalan S, Jaulent AM, Wells M, Veprintsev DB, Fersht AR. 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res 2008, 36(18):5983-5991. 10.1093/nar/gkn598, 2566891, 18812399.
57. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267(5203):1498-1502. 10.1126/science.7878469, 7878469.